The SARM1 targeting therapeutics market is projected to grow at a CAGR of 102.1%, during the period 2033-2040, claims Roots Analysis
SARM1 inhibitors, having demonstrated the ability to prevent axonal degeneration, are being evaluated for the treatment of a number of neurodegenerative disorders. Once approved, these therapies are likely to capture a significant market share
For additional details, please visit https://www.rootsanalysis.com/....reports/sarm1-inhibi or email sales@rootsanalysis.com
Like
Comment
Share
